Analytical and clinical performance evaluation of enhanced chemiluminescence-based fourth-generation HIV combo assay: Report from tertiary health-care setup in North India.
Aseem Kumar Tiwari, Geet Aggarwal, Swati Pabbi, Subhasis Mitra, Neeti Yadav, Virendra Verma, K Cheirmaraj
{"title":"Analytical and clinical performance evaluation of enhanced chemiluminescence-based fourth-generation HIV combo assay: Report from tertiary health-care setup in North India.","authors":"Aseem Kumar Tiwari, Geet Aggarwal, Swati Pabbi, Subhasis Mitra, Neeti Yadav, Virendra Verma, K Cheirmaraj","doi":"10.4103/ajts.ajts_128_22","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>HIV fourth-generation assay, designed for the detection of HIV p24 antigen along with anti-HIV antibodies of both immunoglobulin M and immunoglobulin G type against HIV 1 and HIV 2 viral antigens, have helped in the early detection of HIV infection and supports in minimizing the transmission risk in the acute phase of infection. The objective of this study was to evaluate the analytical and clinical performance of HIV fourth-generation assay based on enhanced chemiluminescence technology.</p><p><strong>Materials and methods: </strong>The analytical performance of the assay was evaluated in terms of accuracy, precision, limit of detection, type of sample (serum vs. plasma), cross-reactivity (with other transfusion transmissible infections markers), and interference (with endogenous substances). Proficiency control material included kit-controls, archived known positive donor samples, third-party controls, and World Health Organization (WHO)/National Institute for Biological Standards and Controls (NIBSC, MHRA, UK) controls. The clinical performance was evaluated using routine donor and patient samples received during the study period.</p><p><strong>Results: </strong>HIV fourth-generation assay showed reliable and reproducible results measured in terms of coefficient of variation % with kit-controls, archived known positive donor samples, third-party controls, and WHO international standards for anti-HIV 1 and 2 antibodies, HIV1 p24 antigens and HIV2 p26 antigen controls. The analytical sensitivity of the HIV fourth-generation assay was found to be 0.1 IU/mL of HIV1 p24 antigen control and there was no cross-reactivity or interference observed. In the clinical performance of the assay, HIV fourth-generation assay showed reliable performance in both donor and patient samples.</p><p><strong>Conclusion: </strong>HIV fourth-generation assay meets the requirements for its use as a screening assay for HIV infection based on the analytical and clinical performance of the assay.</p>","PeriodicalId":42296,"journal":{"name":"Asian Journal of Transfusion Science","volume":"17 2","pages":"175-181"},"PeriodicalIF":0.6000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10807524/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Transfusion Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ajts.ajts_128_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/11 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: HIV fourth-generation assay, designed for the detection of HIV p24 antigen along with anti-HIV antibodies of both immunoglobulin M and immunoglobulin G type against HIV 1 and HIV 2 viral antigens, have helped in the early detection of HIV infection and supports in minimizing the transmission risk in the acute phase of infection. The objective of this study was to evaluate the analytical and clinical performance of HIV fourth-generation assay based on enhanced chemiluminescence technology.
Materials and methods: The analytical performance of the assay was evaluated in terms of accuracy, precision, limit of detection, type of sample (serum vs. plasma), cross-reactivity (with other transfusion transmissible infections markers), and interference (with endogenous substances). Proficiency control material included kit-controls, archived known positive donor samples, third-party controls, and World Health Organization (WHO)/National Institute for Biological Standards and Controls (NIBSC, MHRA, UK) controls. The clinical performance was evaluated using routine donor and patient samples received during the study period.
Results: HIV fourth-generation assay showed reliable and reproducible results measured in terms of coefficient of variation % with kit-controls, archived known positive donor samples, third-party controls, and WHO international standards for anti-HIV 1 and 2 antibodies, HIV1 p24 antigens and HIV2 p26 antigen controls. The analytical sensitivity of the HIV fourth-generation assay was found to be 0.1 IU/mL of HIV1 p24 antigen control and there was no cross-reactivity or interference observed. In the clinical performance of the assay, HIV fourth-generation assay showed reliable performance in both donor and patient samples.
Conclusion: HIV fourth-generation assay meets the requirements for its use as a screening assay for HIV infection based on the analytical and clinical performance of the assay.
导言:第四代 HIV 检测试剂盒设计用于检测 HIV p24 抗原以及针对 HIV 1 和 HIV 2 病毒抗原的免疫球蛋白 M 型和免疫球蛋白 G 型抗 HIV 抗体,有助于早期检测 HIV 感染并在感染急性期将传播风险降至最低。本研究旨在评估基于增强化学发光技术的第四代 HIV 检测方法的分析和临床性能:从准确度、精密度、检测限、样本类型(血清与血浆)、交叉反应(与其他输血传播感染标记物)和干扰(与内源性物质)等方面评估了该检测方法的分析性能。能力对照材料包括试剂盒对照、存档的已知阳性供体样本、第三方对照以及世界卫生组织(WHO)/英国国家生物标准与控制研究所(NIBSC,MHRA,UK)对照。使用研究期间收到的常规捐献者和患者样本对临床性能进行了评估:结果:第四代艾滋病毒检测法与试剂盒对照品、已知阳性捐献者存档样本、第三方对照品以及世界卫生组织抗艾滋病毒 1 和 2 抗体、HIV1 p24 抗原和 HIV2 p26 抗原对照品的变异系数(%)相比,结果可靠且可重复。第四代艾滋病毒检测法的分析灵敏度为 0.1 IU/毫升(HIV1 p24 抗原对照),未发现交叉反应或干扰。在检测的临床表现方面,第四代艾滋病毒检测法在供体和患者样本中均表现出可靠的性能:结论:根据第四代 HIV 检测试剂盒的分析和临床表现,该试剂盒符合用作 HIV 感染筛查试剂盒的要求。